Focus on Alzheimer’s Disease
Alzheimer’s Disease and Neurodegenerative Disorders
Our Areas of Interest for Collaboration
| Disease- Modifying Activity | Symptomatic Treatment of Cognitive Impairment and Neuropsychiatric Conditions | Biomarkers and Diagnostics |
|---|
- Agents in preclinical stage or later should have preclinical validated in vivo, proof-of-concept data
- Amyloid and tau modulators
- Synaptic & cellular resilience
- ApoE4
- Neuroinflammation related pathways
- Therapeutics targeting well-validated human genetic risk factors
| - Novel agents with Phase 2 proof-of- concept in neuropsychiatric symptoms or neuropsychiatric symptoms with cognitive impairment that exhibit superior efficacy to standard of care (e.g., antipsychotics, acetylcholinesterase inhibitors) as monotherapy or adjunctive therapy with synergistic efficacy.
| - Prognostic, diagnostic and disease progression biomarkers
- Diagnostic imaging agents, including imaging of disease pathology, structural and functional MRI
- Improved cerebrospinal fluid and blood biomarker assays
|
